

EQA round: AP1/26 - Antithrombotic Agents

Deadline: 27.3.2026

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average

AV = assigned value

D_{max} = acceptable difference

SD = standard deviation

CVP = consensus of all participants

LL = lower limit

CV = coefficient of variation

U_{AV} = expanded uncertainty of the assigned value (k = 2)

UL = upper limit

N_{tot} = total number of the resultsN_{eva} = number of the results assessedN_{out} = number of the results removed before calculationN_{suc} = number of successful resultsS_{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL				
Set 1															
(108) Apixaban	[µg/L]				61								61	60	98
Sample A1		67	6,6	9,9	61		CVP	67	2,1	25%	50,2	83,8	61	60	98
(38) Werfen (IL)		75,3	3,3	4,4	14	0							14		
(94) Stago		61,5	5,2	8,4	9	0							9		
(149) Siemens (Dade, BN, Dimension)		65,4	4,3	6,5	28	0							28		
(179) Siemens		65	3	4,6	9	0							9		
Other					1	0							1		
							1x 193								
Sample B1		274	14	5,2	61		CVP	274	4,5	25%	205	343	61	61	100
(38) Werfen (IL)		284	9,2	3,3	14	0							14		
(94) Stago		278	14	5,2	9	0							9		
(149) Siemens (Dade, BN, Dimension)		271	14	5,2	28	0							28		
(179) Siemens		265	6,7	2,5	9	0							9		
Other					1	0							1		
							1x 193								
Set 2															
(109) Dabigatran	[µg/L]				39								39	37	95
Sample A2		46,2	5,3	11	39		CVP	46,2	2,1	30%	32,3	60,1	39	37	95
(38) Werfen (IL)		45,6	1,1	2,5	10	0							10		
(149) Siemens (Dade, BN, Dimension)		47,8	6	13	13	0							13		
(179) Siemens		49,5	13	25	7	0							7		
(193) HYPHEN BioMed		42	10	25	8	0							8		
Other					1	1							1		
							1x 94								
Sample B2		183	13	6,9	39		CVP	183	5	30%	128	238	39	39	100
(38) Werfen (IL)		174	8,6	5	10	0							10		
(149) Siemens (Dade, BN, Dimension)		185	5,9	3,2	13	0							13		
(179) Siemens		182	8,2	4,5	7	0							7		
(193) HYPHEN BioMed		197	27	13	8	0							8		
Other					1	0							1		
							1x 94								
Set 3															
(110) Rivaroxaban	[µg/L]				64								64	62	97
Sample A3		81,5	4,9	6	64		CVP	81,5	1,5	25%	61,1	102	64	63	98
(38) Werfen (IL)		86,9	3,8	4,4	16	0							16		
(94) Stago		76,8	4,7	6,1	9	0							9		
(149) Siemens (Dade, BN, Dimension)		79,9	3,8	4,8	29	0							29		
(179) Siemens		83	3	3,6	9	0							9		
Other					1	0							1		
							1x 193								
Sample B3		318	19	6	64		CVP	318	5,9	25%	238	398	64	63	98
(38) Werfen (IL)		320	10	3,2	16	0							16		
(94) Stago		347	19	5,3	9	0							9		
(149) Siemens (Dade, BN, Dimension)		311	15	5	29	0							29		
(179) Siemens		301	14	4,6	9	0							9		
Other					1	0							1		
							1x 193								